重组 DNA 技术市场规模、份额和成长分析（按产品、组件、应用、最终用途和地区）- 产业预测 2025-2032

预计2023年全球重组 DNA 技术市场规模将达到 1,555 亿美元，并从 2024 年的 1,671.6 亿美元成长到 2032 年的 2,981.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.5%。

重组 DNA（rDNA）技术彻底改变了基因资料管理，实现了生物技术和製药领域的多种应用。最近的进展使得生产重组药物不再需要人类捐赠者，例如用于糖尿病管理的转基因胰岛素的商业性成功。随着慢性病成本的上升，业界正在利用 rDNA 技术寻找创新治疗方案。特别是，正在开发使用 CRISPR/Cas9、ZFN 和 TALEN 技术的重组蛋白，以增强生物製药的进步和精准基因组编辑。此外，全球基改作物面积的不断扩大，证实了rDNA在农业领域的成功，其应用范围也扩展到生质燃料和应对环境挑战的生物农药。然而，关于基因治疗及其技术的使用的伦理问题在许多领域一直存在争议。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

重组 DNA 技术市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 医疗
  • 治疗
  • 人类蛋白质
  • 疫苗
• 非医疗
  • 生物技术作物
  • 特种化学品
  • 其他非医疗产品

重组 DNA 技术市场规模（按组件和复合年增长率） (2025-2032)

• 市场概况
• 表达系统
  • 哺乳类
  • 细菌
  • 酵母菌
  • 桿状病毒/昆虫
  • 其他表达系统
• 克隆载体

重组 DNA 技术市场规模（按应用划分）及复合年增长率（2025-2032）

• 市场概况
• 食品和农业
• 健康与疾病
  • 人类
  • 动物
• 环境
• 其他用途

重组 DNA 技术市场规模（按最终用途和复合年增长率划分）（2025-2032 年）

• 市场概况
• 生技及製药公司
• 学术和政府研究组织
• 其他最终用途

重组 DNA 技术市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Thermo Fisher Scientific（US）
• Roche Holding AG（Switzerland）
• Merck KGaA（Germany）
• Agilent Technologies（US）
• Bio-Rad Laboratories（US）
• Illumina（US）
• Danaher Corporation（US）
• Sartorius AG（Germany）
• Lonza Group（Switzerland）
• Charles River Laboratories（US）
• GenScript Biotech Corporation（China）
• Twist Bioscience（US）
• Ginkgo Bioworks（US）
• Amyris（US）
• Synthetic Genomics（US）
• Intrexon（US）
• PerkinElmer（US）
• Eurofins Scientific（Luxembourg）

结论和建议

Global Recombinant DNA Technology Market size was valued at USD 155.5 billion in 2023 and is poised to grow from USD 167.16 billion in 2024 to USD 298.13 billion by 2032, growing at a CAGR of 7.5% during the forecast period (2025-2032).

Recombinant DNA (rDNA) technology has transformed genetic data control, allowing for various applications across the biotech and pharmaceutical landscapes. Recent advancements have enabled the successful production of recombinant medications without human donors, highlighted by the commercial success of genetically modified insulin for diabetes management. As chronic disease costs rise, the industry is leveraging rDNA methods for innovative therapeutic solutions. The ongoing development of recombinant proteins, particularly using CRISPR/Cas9, ZFN, and TALEN technologies, enhances biopharmaceutical advancements and precision genome editing. Additionally, the global expansion of GM crop acreage underscores rDNA's success in agriculture, with applications extending to biofuels and biopesticides for environmental challenges. However, ethical concerns regarding gene therapy and technology usage present ongoing debates across various sectors.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Recombinant Dna Technology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Recombinant Dna Technology Market Segments Analysis

Global Recombinant DNA Technology Market is segmented by Product, Component, Application, End Use and region. Based on Product, the market is segmented into Medical and Non-medical. Based on Component, the market is segmented into Expression System and Cloning Vector. Based on Application, the market is segmented into Food & Agriculture, Health & Disease, Environment and Other Applications. Based on End Use, the market is segmented into Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes and Other End Uses. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Recombinant Dna Technology Market

The growth of the global recombinant DNA technology market during the forecast period is anticipated to be significantly influenced by an increase in strategic partnerships among major industry players. These collaborations aim to advance the development of recombinant DNA technologies and often involve partnerships with prominent biopharmaceutical companies and research institutions to create innovative therapeutics. Such collective efforts and strategic alliances within the market are expected to facilitate advancements and drive expansion in the sector, leading to new opportunities and a heightened competitive landscape in the field of recombinant DNA technology.

Restraints in the Global Recombinant Dna Technology Market

The growth of the Global Recombinant DNA Technology market is being hindered by several factors, primarily the high costs associated with gene therapy. Additionally, potential side effects, such as Cytokine Release Syndrome (CRS) and neurotoxicity, pose significant challenges. The anticipated expansion of the market is further limited by various ethical, legal, and scientific constraints surrounding gene therapy applications. These restrictions not only impact research and development efforts but also contribute to hesitation among stakeholders, ultimately affecting the overall progress and acceptance of recombinant DNA technologies within the healthcare landscape.

Market Trends of the Global Recombinant Dna Technology Market

The Global Recombinant DNA Technology market is witnessing a significant upward trend driven by increasing public acceptance of genetically modified crops aimed at enhancing agricultural yield and pest resistance. Pioneering initiatives, such as the licensing of the genetically modified tomato CGN-89564-2 for human consumption, are paving the way for broader applications across various sectors. The intersection of DNA molecular marker technologies further facilitates the identification and innovation of valuable plant germplasm resources. This surge in research and application of GMOs, particularly in food, agriculture, and medicine, underscores the potential of recombinant DNA technology to revolutionize health care and biomedicine, creating lucrative opportunities for market stakeholders.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant DNA Technology Market Size by Product & CAGR (2025-2032)

• Market Overview
• Medical
  • Therapeutic Agent
  • Human Protein
  • Vaccine
• Non-medical
  • Biotech Crops
  • Specialty Chemicals
  • Other Non-medical Products

Global Recombinant DNA Technology Market Size by Component & CAGR (2025-2032)

• Market Overview
• Expression System
  • Mammalian
  • Bacteria
  • Yeast
  • Baculovirus / Insect
  • Other Expression Systems
• Cloning Vector

Global Recombinant DNA Technology Market Size by Application & CAGR (2025-2032)

• Market Overview
• Food & Agriculture
• Health & Disease
  • Human
  • Animal
• Environment
• Other Applications

Global Recombinant DNA Technology Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Biotechnology and Pharmaceutical Companies
• Academic & Government Research Institutes
• Other End Uses

Global Recombinant DNA Technology Market Size & CAGR (2025-2032)

• North America (Product, Component, Application, End Use)
  • US
  • Canada
• Europe (Product, Component, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Component, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Component, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Component, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Twist Bioscience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ginkgo Bioworks (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amyris (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synthetic Genomics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intrexon (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations